Need an expert perspective on cancer science, policy, or patient care? ASCO experts are knowledgeable on a wide variety of cancer topics. Expert Connect showcases a selection of the experts ASCO has available for media interviews. If you’d like to interview one of the experts below, or you’re uncertain about who you’d like to speak with, please email ASCO's Media Team, and we will do our best to connect you with the appropriate expert.
Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through research, education, and promotion of the highest quality, equitable patient care by the Society’s nearly 50,000 members.
Read Dr. Hudis’ Q&A on ASCO Connection.
View current ASCO disclosure here.
Dr. Gralow is the Chief Medical Officer (CMO) and Executive Vice President of ASCO, and brings to her role deep expertise in patient care, research, education, and global health.
Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.
Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women’s Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington’s Department of Global Health, as a member of the University of Washington’s Breast Cancer Equity Initiative, as Medical Director for Women’s Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute’s adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.
She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.
Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.
She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.
Dr. Gralow received her bachelor’s degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at University of Washington/Fred Hutchinson Cancer Research Center in Seattle.
Dr. Schuchter is chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, director of the Tara Miller Melanoma Center at the Abramson Cancer Center, and the Madlyn and Leonard Abramson Professor of Clinical Oncology at the Perelman School of Medicine of the University of Pennsylvania. Dr. Schuchter is a clinical investigator in the area of melanoma and has a strong commitment to mentorship. Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012. She has served on numerous ASCO committees, including terms as chair of Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee, and as an editor on the Journal of Clinical Oncology Editorial Board. In 2019, she was recognized with the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation.
View current ASCO disclosure here.
Dr. Zon currently serves as the Director of Breast Cancer Oncology at the Cincinnati Cancer Advisors (CCA), a provider of no-cost second opinions to recently diagnosed cancer patients in or near the Greater Cincinnati area. Prior to joining CCA, Dr. Zon served as Past President, and is now Physician Emeritus at Michiana Hematology Oncology in Mishawaka, IN. She formerly served as Medical Director of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI designated Community Cancer Oncology Program in the state of Indiana. Dr. Zon is an active volunteer for ASCO, most recently being awarded ASCO’s Advocate of the Year for her significant advocacy work on behalf of individuals living with cancer and their cancer care teams and was the recipient of ASCO’s Distinguished Achievement Award. Dr. Zon is a Past Chair of ASCO’s Government Relations Committee, where she provided distinguished leadership in the society’s advocacy efforts. She also served on the Board of Directors from 2010 to 2013, along with participating in many other ASCO related responsibilities.
View current ASCO disclosure here
Dr. Winer was elected to serve as the ASCO President in 2022-2023. He is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven. Before then, he served as the chief clinical development officer, senior vice president for medical affairs, Director of the Dana-Farber/Harvard SPORE in Breast Cancer, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He has also served as a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture in 2017 and the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.
View current ASCO disclosure here.
Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.
View current ASCO disclosure here
Dr. Carey is Deputy Director for Clinical Sciences at Lineberger Comprehensive Cancer Center and the L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also co-chair of the Alliance cooperative group Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Society’s Audit Committee and the Journal of Clinical Oncology editorial board.
View current ASCO disclosure here
Dr. Aggarwal is the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine. She specializes in lung cancer management, with a clinical research focus on developing personalized therapeutic approaches and the discovery and application of biomarkers to guide treatment.
Dr. Aggarwal is a world-renowned expert in the application of plasma-based gene sequencing for managing patients with metastatic lung cancer. Her current work involves implementing comprehensive testing and discovering approaches for early detection, detection of resistance mutations, and monitoring disease progression.
As the Associate Director of the Penn Center for Precision Medicine and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I), Dr. Aggarwal is actively involved in developing, implementing, and advancing strategic and operational precision medicine initiatives, focusing those introducing new technologies or approaches to clinical care. Her aim is to fulfill the promise of personalized cancer therapy.
In her clinical trials, Dr. Aggarwal emphasizes patient-centric, scientifically relevant advancements in novel immunotherapy. Her work is dedicated to making a tangible impact and advancing our understanding of immunotherapy treatments for patients with lung cancer.
Dr. Mayer received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Medical Oncology at Dana-Farber Cancer Institute. She obtained a Master's in Public Health from the Harvard School of Public Health in 2005.
Since joining the staff of Dana-Farber and Brigham and Women's Hospital in 2006, Dr. Mayer has been serving as a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on the development and assessment of novel therapies in the treatment of breast cancer, contributing to significant advancements in the field.
Dr. Ahluwalia is the chief of solid tumor medical oncology as well as chief scientific officer and deputy director of Miami Cancer Institute, and a professor of translational medicine at Herbert Wertheim College of Medicine, Florida International University. He is a member of the ASCO Plenary Series Review Committee and the Evidence-Based Medicine Committee, and serves as a specialty editor for central nervous system tumors for Cancer.Net, ASCO’s patient information website, among additional past volunteer service. Dr. Ahluwalia is a past participant in the ASCO Leadership Development Program.
Dr. Byers is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and is an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas. She earned her B.A. in Molecular Biology from Princeton University, followed by an M.D. at Baylor College of Medicine, and her M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences.
Dr. Byers is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group.
Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers. Her research primarily targets drugs that affect DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer.
As a physician-scientist, her landmark research has revealed critical differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC.
Dr. Chino is a dedicated cancer researcher and Assistant Attending in Radiation Oncology at Memorial Sloan Kettering Cancer Center, where she also leads the Affordability Working Group. Her research is primarily centered on patient-centered care, with a special focus on the financial toxicity associated with cancer care and survivorship. Additionally, she is deeply involved in studies addressing healthcare disparities, equity, and access.
In her clinical role, Dr. Chino specializes in the treatment of breast and gynecological cancers, applying her extensive research knowledge to provide comprehensive care for her patients.
Dr. Campbell serves as a Professor of Medicine and a Thoracic Oncologist at the University of Wisconsin - Madison. In addition, he holds the positions of Chief of Palliative Care and the Ellen and Peter O. Johnson chair in Palliative Care. His expertise lies in facilitating complex conversations including delivering difficult news, leading family meetings, and guiding high-risk decision-making processes.
His interdisciplinary work in communication has led to contributions in an array of journals spanning medical, surgical, and communication fields. Dr. Campbell’s efforts in enhancing communication practices have significantly influenced both clinical and academic realms.
Dr. Elizabeth Comen is a Medical Oncologist at Memorial Sloan Kettering Cancer Center, where she specializes in breast cancer. Renowned internationally, she is a clinician and physician-scientist recognized for her compassionate patient care and clear communication. She is also an Assistant Professor of Medicine at Weill Cornell Medical College.
Dr. Comen earned a BA in the History of Science from Harvard College and an MD from Harvard Medical School. She completed her residency in Internal Medicine at Mount Sinai Hospital and her fellowship in oncology at Memorial Sloan Kettering Cancer Center. In conjunction with her breast cancer research, Dr. Comen studies aging in the immune system and its influence on cancer and other diseases.
Her research findings have been showcased at major cancer conferences globally, including the American Society of Clinical Oncology’s. Recognized for excellence in her field, Dr. Comen has been named a Castle Connolly Top Doctor in New York for the past five years.
Dr. Comen’s insights have reached a broad audience through her appearance on national television programs such as Good Morning America, The Today Show, The View, ABC News, NY1, Wall Street Journal online, Fox News, and she has been featured in media outlets including the New York Times, Today.com, Elle Magazine, and Self Magazine. Dr. Comen was also featured in a widely broadcast television commercial and print advertisement for Memorial Sloan Kettering Cancer Center over the past several years.
Dr. Deville is an Associate Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. He serves as Clinical Director of Sibley Radiation Oncology and Medical Director of the Johns Hopkins Proton Therapy Center.
His clinical expertise is focused on the treatment of prostate cancer and soft tissue sarcoma. Dr. Deville actively engages in funded research, aiming to improve tumor targeting and assessing toxicity profiles using modern radiation techniques such as proton and photon therapy. He has co-authored over 150 peer-reviewed publications and serves as a Deputy Editor for the International Journal of Radiation Oncology, Biology, Physics.
Apart from his clinical and research endeavors, Dr. Deville is deeply invested in advancing health equity, exploring physician workforce diversity as a leading voice in health equity, diversity, and inclusion (HEDI) in Radiation Oncology, Dr. Deville continues to lead and inspire in this vital aspect of healthcare.
Since joining the Sarah Cannon Research Institute in 2003 as the Chief Scientific Officer, Dr. Spigel has been instrumental in overseeing the scientific aspects of institute’s clinical trial program. His role involves working closely with research physician leaders to ensure access to the latest and most effective new agents and studies for patients. As a key liaison, he connects with pharmaceutical and biotech partners as well as strategic site physicians collaborating on cancer research with Sarah Cannon.
Dr. Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992. He then received his medical degree from The University of Tennessee in Memphis in 1996. After completing internal medicine and chief residencies at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology.
In addition to his role at Sarah Cannon, Dr. Spigel is a partner with Tennessee Oncology, PLLC.
Dr. Fleming is a board-certified Medical Oncologist who joined Virginia Oncology Associates (VOA) in August 2006. He received his B.A. at the University of Pennsylvania in Philadelphia before pursuing his Doctorate in Medicine at Medical University of Ohio. Dr. Fleming completed his residency at Temple University Hospital in Philadelphia, PA, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY.
Dr. Fleming specializes in bladder cancer, kidney cancer, prostate cancer, and testicular cancer. He is also involved in Phase 1 drug development. He is heavily involved in cancer research, serving as a principal investigator for clinical trials, both locally and nationally. His collaborative efforts with institutions like Duke University Network, Hoosier Oncology Group, Prostate Cancer Clinical Trials Consortium, and The US Oncology Research enable him to provide the latest treatment options to patients.
Dr. Hanna, an alumnus of Georgetown University School of Medicine, graduated summa cum laude in 2010. During his time there, he was inducted into the Alpha Omega Alpha Honor Society and received the prestigious Kober Medalist for academic excellence. He completed his fellowship in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. In 2017, he joined the faculty of the Center for Head and Neck Oncology.
Dr. Hanna's research is primarily advancing precision medicine in the treatment of head and neck cancers. He is dedicated to the discovery of both molecular and immunologic biomarkers aiming to improve patient outcomes. He maintains foundation and industry support to explore innovative immuno-oncology approaches to treat head and neck cancers and high-risk oral precancerous lesions. This involves developing novel combinations of immune checkpoint blockade, intra-tumoral injectables, and immune effector cell (IEC) therapies.
Additionally, Dr. Hanna has an interest in applying precision medicine to treat salivary gland cancers of the head and neck, and in using cell-free DNA to treat and monitor human papillomavirus (HPV)-associated head and neck cancers.
Dr. Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine. She is also the Director of the Center for Gastrointestinal Oncology at Yale Cancer Center and Smilow Cancer Hospital. Dr. Kunz received her medical degree from the Dartmouth Geisel School of Medicine, followed by a medical residency, chief residency and oncology fellowship at Stanford University School of Medicine.
Dr. Kunz is an international leader in the treatment and clinical research of gastrointestinal (GI) malignancies and neuroendocrine tumors (NETs). She holds key leadership positions in the field including Chair of the Neuroendocrine Tumor Taskforce of the National Cancer Institute (NCI) and Vice President of the North American Neuroendocrine Tumor Society.
In addition, Dr. Kunz is a leading voice for promoting gender equity in the medical profession. She serves as the Vice Chief for DEI for the Section of Medical Oncology at Yale. Her efforts in this area were recently recognized when she received the prestigious award of Woman Oncologist of the Year from Women Leaders in Oncology.
Dr. Lowe is an Associate Professor in the Division of Surgical Oncology at Emory University School of Medicine’s Department of Surgery. As a board-certified surgeon, he focuses primarily on cutaneous malignancies in his role at Winship Cancer Institute. He joined Emory after completing a fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center in New York, NY.
In the professional community, Dr. Lowe is an active member of several prominent organizations, including the American Society of Clinical Oncology, the Association of Academic Surgery, the Society of Surgical Oncology and the American College of Surgeons. His research focuses on neoadjuvant therapies for cutaneous malignancies. Dr. Lowe leads as the principial investigator on numerous investigator-initiated, industry-sponsored, and cooperative group clinical trials.
Dr. Lowe is the Medical Director of the Emory Morningside Center for Innovative and Affordable Medicine, which supports clinical trials using repurposed drugs in combination with conventional cancer therapies. He serves as the Director of Extramural Research Studies for the Emory University General Surgery Residency, guiding the next generation of surgical researchers.
Dr. McGregor is a Medical Oncologist at Dana-Farber Cancer Institute specializing in genitourinary malignancies. He completed his undergraduate and medical school education at Tufts University; he then joined the United States Air Force at the San Antonio Uniformed Services Health Education Consortium.
While in the military, Dr. McGregor completed post-graduate training in internal medicine, medical oncology and hematology. He provided oncologic care to active-duty members, their family members, and retirees, addressing a broad range of conditions in benign hematology and medical oncology in San Antonio, TX and at Travis Air Force Base in Northern California.
He served in Afghanistan as the Deputy Commander for the NATO led Medical Training Advisory Group where he mentored Afghan physicians. Dr. McGregor achieved the rank of Lieutenant Colonel and was honored with the Meritorious Service medal.
In July 2016, Dr McGregor transitioned from the Air Force to join Dana-Farber Cancer Institute. Initially appointed as the Clinical Director of the Lank Center for Genitourinary Oncology, he now is the Director of Clinical Research. In this capacity, he has served as principal investigator for several trials, notably leading Investigator-Initiated Trials (IITs) in the treatment of rare genitourinary malignancies, including non-clear cell renal cell carcinoma.
Steven is an 11-year survivor of stage IV pancreatic cancer. After a Whipple procedure and aggressive chemotherapy, he was the first person in the United States to enroll in a clinical trial for a specific PARP inhibitor which was very successful for him. Once the bulk of his treatments were behind him, his next focus was on patient advocacy. In 2017, he attended his first PanCAN Advocacy event in Washington, D.C., and in 2019 became a state group leader meeting members of the House of Representative or their staff.
A 40-year career in clinical cancer, immunology and stem cell research at academic, government and private research foundations in the U.S. and Switzerland has given him a unique perspective on helping others deal with this disease. He is very active in several U.S. and a Canadian-based support group where he explains and answers questions on the biology of cancer, treatments and clinical trials. Steven has received several appointments with various organizations including serving as a patient research advocate on the GI Cancers Committee of the nonprofit cancer research organization ECOG-ACRIN, providing input from a patient perspective during the development and revision of clinical trials and recently joined the ASCO Cancer Communications Committee as a patient advocate.
Now retired from his career in research, Steven concentrates on mentoring those newly diagnosed with pancreatic cancer and helping both patient and caregiver navigate treatment and make them aware of possible options. He has contact with patients worldwide and has actively promoted the many programs and services the Pancreatic Cancer Action Network offers.
Dr. Odejide is a hematologic oncologist within the Center for Lymphoma, Dana-Farber Cancer Institute, and an Assistant Professor of Medicine at Harvard Medical School. She earned her medical degree from Howard University in Washington, DC, and completed her internal medicine residency at Brigham and Women’s Hospital in Boston, MA. Furthering her specialization, she pursued a hematology/oncology fellowship at the Dana-Farber/Mass General Brigham Program, while also completing her MPH degree from the Harvard T.H. Chan School of Public Health.
Dr. Odejide research focuses on health outcomes and health services, particularly in developing interventions to improve quality of life and care for patients with hematologic malignancies. Her work spans a broad spectrum, from developing strategies to improve palliative and end-of-life care to investigating factors that promote effective psychosocial coping for patients diagnosed with lymphoma. Her commitment to this field is evident in her multidisciplinary approach and dedication to advancing patient care throughout the various stages of their illness.
Dr. Schiff’s clinical and research career has focused on the study and treatment of primary and metastatic brain and spinal cord tumors. Since 2002, he has been at the forefront of developing and leading the medical neuro-oncology program at the University of Virginia.
His clinical research is particularly focused on conducting clinical trials aimed at advancing treatments for glioblastoma and lower-grade gliomas. Notably, Dr. Shiff has played a pivotal role in significant trials such as BRAIN, EF-11, and EF-14. His contributions have been instrumental in the FDA’s approvals of bevacizumab and the Novocure Tumor Treating Fields (TTF) device, both significant advancements in glioblastoma therapy.
Dr. Teplinsky is a board-certified medical oncologist leading the Breast and Gynecologic Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, NJ. She is a Clinical Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York.
Her clinical and research interests focus on young women with breast and gynecologic cancers. Dr. Teplinsky has a strong interest in cancer survivorship, focusing on how patients can maintain and improve their quality-of-life post-treatment. Additionally, she is actively involved in exercise oncology, exploring the role of physical activity in cancer care and recovery. Dr. Teplinsky is also an advocate for utilizing social media as a tool in oncology, recognizing its potential in patient education, engagement, and community support.
Dr. Tseng is a surgical oncologist whose practice includes pancreas, hepatobiliary, and gastric surgery. She is also a health services researcher focusing on risk prediction and prevention, disparities in surgical and cancer care, and models to build health equity. Dr. Tseng founded the Surgical Outcomes Analysis & Research (SOAR) initiative in 2007. SOAR is now the hub of outcomes research for the Chobanian & Avedisian School of Medicine/BMC Department of Surgery.